These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 31958251)
1. A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. Koehl JL; Hayes BD; Al-Samkari H; Rosovsky R Expert Rev Hematol; 2020 Feb; 13(2):155-173. PubMed ID: 31958251 [No Abstract] [Full Text] [Related]
2. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521 [TBL] [Abstract][Full Text] [Related]
3. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach. Rollins BM; Silva MA; Donovan JL; Kanaan AO Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394 [TBL] [Abstract][Full Text] [Related]
7. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197 [TBL] [Abstract][Full Text] [Related]
8. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. King DA; Pow RE; Dickison DM; Vale PR Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450 [TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376 [TBL] [Abstract][Full Text] [Related]
10. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study. Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116 [TBL] [Abstract][Full Text] [Related]
11. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study. Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043 [TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350 [TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location. Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335 [TBL] [Abstract][Full Text] [Related]
14. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207 [TBL] [Abstract][Full Text] [Related]
15. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Weycker D; Wygant GD; Guo JD; Lee T; Luo X; Rosenblatt L; Mardekian J; Atwood M; Hanau A; Cohen AT Blood Adv; 2020 Jan; 4(2):432-439. PubMed ID: 31990332 [TBL] [Abstract][Full Text] [Related]
16. The role of apixaban for venous and arterial thromboembolic disease. Prom R; Spinler SA Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450 [TBL] [Abstract][Full Text] [Related]
17. Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside. Poredos P; Jezovnik MK Curr Drug Targets; 2018; 19(6):577-580. PubMed ID: 25981607 [TBL] [Abstract][Full Text] [Related]
18. Drug Treatment of Venous Thromboembolism in the Elderly. Boey JP; Gallus A Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713 [TBL] [Abstract][Full Text] [Related]
19. Apixaban (Eliquis) in deep vein thrombosis and pulmonary embolism. Warfarin remains the standard therapy. Prescrire Int; 2015 Sep; 24(163):206. PubMed ID: 26417627 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Kimpton M; Carrier M Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]